Educational guide
Vesilute vs Prostamax — Peptide Comparison
At a Glance Quickcomparison Dose Range Vesilute 20–40 mg Prostamax 5–10 mg Frequency Once daily Administration Oral (capsule/tablet) Sublingual (enteric-coated capsules) Cycle Length 12+ weeks Onset Speed Gradual (3-4 weeks) Evidence Level Moderate human trial
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
At a Glance
Quickcomparison
Dose Range
Vesilute
20–40 mg
Prostamax
5–10 mg
Frequency
Once daily
Administration
Oral (capsule/tablet)
Sublingual (enteric-coated capsules)
Cycle Length
12+ weeks
Onset Speed
Gradual (3-4 weeks)
Evidence Level
Moderate human trials (Phase 1-2)
Limited human trials
Efficacy
Benefitratings
Bladder Health
Prostate Support
Tissue Repair
Prostate Health
Urinary Function
Tissue Inflammation
Technical Data
Compoundspecifications
Molecular Formula
C9H14N2O7
Molecular Weight
262.2 g/mol
Half-Life
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids via standard pathways
Bioavailability
High oral bioavailability for a dipeptide — absorbed intact by intestinal peptide transporter PepT1 (SLC15A1); ultra-short structure enables efficient cellular uptake and nuclear penetration
CAS Number
3918-84-1
C20H33N5O9
487.5 g/mol
Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through chromatin remodeling at prostate gene promoters; metabolized to constituent amino acids
Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to short tetrapeptide structure with proline conferring conformational stability
Not publicly registered
Protocols
Dosingtiers
starting
1 capsule (10 mg) once daily
Once daily before meals
10-day initial course
Khavinson ED (Glu-Asp) urogenital dipeptide bioregulator; absorbed intact via PepT1 transporter [6]. Research/wellness use, not FDA-approved.
standard
2 capsules (20 mg) daily
1–2 times daily before meals
20–30 day course
Standard daily dose; courses repeated every 2–6 months [6]. Sublingual administration also used for buccal uptake.
advanced
10–20 mg per week (split into 2–3 injections)
2–3 times weekly
Injectable practice protocol for direct systemic delivery of the ED dipeptide [6]. Research use only.
0.01-100 mcg/kg
10-40 days
Dose from a single-institute patent report in 35 chronic-prostatitis patients [6]. The wide range reflects dose-finding within that single report.
~10 mg
10-30 day course
Capsule form reflecting bioregulator product labeling and practice [1].
Applications
Bestsuited for
Supporting bladder health and urinary function in aging individuals
Vesilute is particularly well-suited for individuals focused on supporting bladder health and urinary function in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Bioregulatory approach to benign prostatic hyperplasia (BPH) management
Vesilute is particularly well-suited for individuals focused on bioregulatory approach to benign prostatic hyperplasia (bph) management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic urogenital inflammation through epigenetic mechanisms
Vesilute is particularly well-suited for individuals focused on reducing chronic urogenital inflammation through epigenetic mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing standard urological treatments with peptide bioregulator therapy
Vesilute is particularly well-suited for individuals focused on complementing standard urological treatments with peptide bioregulator therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
Prostamax is particularly well-suited for individuals focused on age-related benign prostatic hyperplasia (bph) requiring tissue-level normalization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Prostate geroprotection — preserving prostatic epithelial function during aging
Prostamax is particularly well-suited for individuals focused on prostate geroprotection — preserving prostatic epithelial function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
Prostamax is particularly well-suited for individuals focused on chronic prostatitis support through anti-inflammatory tissue-level mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting male genitourinary health
Prostamax is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male genitourinary health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Sideeffects
Common
Mild gastrointestinal discomfort
Increased urinary frequency initially
Mild headache
Minor fatigue
Uncommon
Injection site irritation
Serious
No documented serious adverse effects
Injection site reaction
Mild fatigue
Urinary frequency changes
Mild pelvic discomfort
Research Status
Safety& evidence
FDA Status
Research compound
Safety Overview
Vesilute (fibroin-derived peptide from Bombyx mori silk) demonstrates favorable biocompatibility from cosmetic ingredient testing with minimal allergic or irritant potential despite its animal protein origin. Limited systemic absorption occurs topically, confining effects to dermal layers with low risk of systemic toxicity. Silk-derived peptides have been used in cosmetics for >20 years without documented serious adverse events in published literature. Theoretical hypersensitivity risk exists for individuals with silk allergy, though cross-reactivity with purified peptide is low.
Contraindications
xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid)
xPregnancy and breastfeeding — insufficient reproductive safety data
xActive urinary tract infection requiring antibiotic treatment — treat infection first
xBladder or prostate malignancy — proliferative effects of peptide bioregulators may be contraindicated
Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence. No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers.
xKnown or suspected prostate cancer — potential modulation of prostatic gene expression requires oncological clearance
xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, proline)
xSevere urinary retention requiring surgical intervention — epigenetic therapy cannot address acute obstruction
xConcurrent anti-androgen therapy without medical supervision — potential interaction with hormonal mechanisms
Decision Guide
Which isright for you?
Choose Vesilute if...
Supporting bladder health and urinary function in aging individuals
Bioregulatory approach to benign prostatic hyperplasia (BPH) management
Reducing chronic urogenital inflammation through epigenetic mechanisms
Complementing standard urological treatments with peptide bioregulator therapy
Choose Prostamax if...
Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
Prostate geroprotection — preserving prostatic epithelial function during aging
Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
Comprehensive Khavinson bioregulator protocols targeting male genitourinary health